Cyclophosphamide Tablets
Formulated to treat lymphoid malignancies; indicated to target rapidly dividing cells to alleviate disease progression.
Strengths: 50mg
Where to Check Availability
Medicine details
- Alternative names
Cyclophosphamide Accord; Cyclophosphamide Sandoz
- Therapeutic class
Alkylating Antineoplastic Agent
- Pharmacological class
Nitrogen Mustard Alkylating Agent
- Contraindications
hypersensitivity to active ingredient; severe bone marrow depression
- Minor side effects
nausea; vomiting; alopecia; leukopenia
- Moderate side effects
haemorrhagic cystitis; infertility
- Dosage forms
Tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Accord Healthcare
- Onset Time
2–3 weeks
- Duration
continuous as prescribed
- Storage instructions
Store below 25°C.
- Drug interactions
alcohol; doxorubicin; pentostatin
- Age restrictions
Not indicated for paediatric use unless specialised.
Precautions and warnings
maintain high fluid intake to prevent bladder toxicity; monitor blood counts regularly
Serious side effects
cardiotoxicity — requires immediate medical attention; secondary malignancy — requires immediate medical attention
Patient summary
Formulated to treat lymphoid malignancies; indicated to target rapidly dividing cells to alleviate disease progression.
Mechanism of action
An alkylating agent that works by adding an alkyl group to DNA. This cross-links DNA strands, preventing cancer cell division and synthesis, ultimately inhibiting the growth and spread of malignant tumours.
Pregnancy and breastfeeding
Pregnancy: must not be used during pregnancy. Breastfeeding: must not be used while breastfeeding.
Cyclophosphamide Tablets
Formulated to treat lymphoid malignancies; indicated to target rapidly dividing cells to alleviate disease progression.
Editorial Notes
- Active ingredient(s): Cyclophosphamide
- Listed indication(s): Malignant Lymphoma, Leukaemia, Ovarian Cancer
Available option
- 30 tablets - 50 mg1361-50-mg-16368